Jemperli (dostarlimab) might be a cancer cure breakthrough from GSK, as it cured 100% of rectal cancer cases in a trial.
GSK announced a significant breakthrough in cancer therapy with its drug Jemperli (dostarlimab), which demonstrated a 100% clinical complete response rate in a phase 2 trial at Memorial Sloan Kettering Cancer Center (MSK).
The study involved 42 patients with mismatch repair deficient (dMMR) locally advanced rectal cancer, showing no evidence of remaining tumors after treatment.
The first 24 patients, monitored for an average of 26.3 months, exhibited no signs of cancer recurrence, making Jemperli a promising first-line alternative to chemotherapy and surgery.
Jemperli, a monoclonal antibody drug, works by binding to immune cells and preventing cancer cells from evading immune detection, allowing the immune system to eradicate the cancerous growths. GSK plans further testing on other types of colorectal cancers.
